loss compound melts fat without curbing appetite — and preserves muscle

Key Points:

• Researchers at the University of California, Berkeley, identified an oral compound called TOFA that led to an average 18% weight loss in obese mice by boosting energy expenditure rather than suppressing appetite.
• TOFA works by blocking enzymes involved in lipid production and activating genes related to fat burning, resulting in increased energy use without reducing activity or causing dangerous body temperature changes.
• Combining TOFA with existing drugs like semaglutide or tirzepatide enhanced weight loss and improved metabolic markers more than either treatment alone, with TOFA-treated mice maintaining weight loss after treatment ended.
• The compound also reduced liver fat, inflammation, and fibrosis in mouse models of fatty liver disease without raising blood triglyceride levels, a common side effect of similar metabolic drugs.
• While promising, TOFA has only been tested in male mice so far, and human safety, appropriate dosing, and potential side effects remain unknown; experts urge caution and note the complexity of obesity and weight regulation.